Citigroup Inc. Boosts Position in Axsome Therapeutics, Inc. $AXSM

Citigroup Inc. raised its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 67.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 142,013 shares of the company’s stock after acquiring an additional 57,002 shares during the period. Citigroup Inc. owned approximately 0.28% of Axsome Therapeutics worth $17,247,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Moors & Cabot Inc. lifted its position in Axsome Therapeutics by 4.5% during the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock valued at $243,000 after purchasing an additional 100 shares during the period. Meridian Wealth Management LLC lifted its holdings in shares of Axsome Therapeutics by 0.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after buying an additional 103 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Axsome Therapeutics by 1.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after buying an additional 107 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Axsome Therapeutics by 6.1% in the third quarter. PNC Financial Services Group Inc. now owns 1,856 shares of the company’s stock worth $225,000 after buying an additional 107 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in Axsome Therapeutics by 0.6% during the third quarter. State of New Jersey Common Pension Fund D now owns 18,158 shares of the company’s stock worth $2,205,000 after acquiring an additional 109 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AXSM. Royal Bank Of Canada boosted their price target on Axsome Therapeutics from $219.00 to $222.00 and gave the company an “outperform” rating in a report on Tuesday. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Robert W. Baird set a $209.00 price target on shares of Axsome Therapeutics in a report on Tuesday, January 13th. UBS Group lifted their price objective on shares of Axsome Therapeutics from $248.00 to $251.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 14th. Seventeen analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.12.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $163.89 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. The stock has a market capitalization of $8.38 billion, a PE ratio of -44.41 and a beta of 0.40. Axsome Therapeutics, Inc. has a fifty-two week low of $86.99 and a fifty-two week high of $191.50. The company has a fifty day moving average of $175.78 and a two-hundred day moving average of $146.07.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, February 23rd. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 232.61%. The business had revenue of $196.00 million during the quarter, compared to analysts’ expectations of $191.33 million. The business’s quarterly revenue was up 65.0% compared to the same quarter last year. As a group, research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 32,410 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $185.60, for a total transaction of $6,015,296.00. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $1,341,702.40. The trade was a 81.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark Coleman sold 25,000 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $161.11, for a total value of $4,027,750.00. Following the completion of the transaction, the director directly owned 47,140 shares of the company’s stock, valued at approximately $7,594,725.40. This represents a 34.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 369,252 shares of company stock worth $61,145,545 in the last quarter. Corporate insiders own 22.30% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.